FDA
-
-
-
-
-
-
-
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront
-
-
-
-
-
-
-
Jazz Pharmaceuticals to present 21 abstracts at SLEEP 2026 conference
-
-
-
-
-
-
-
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
-
-
-
-
-
-
-
Jazz Pharmaceuticals reports positive Ziihera cancer trial results
-
-
-
-
-
-
-
JAZZ reports positive phase 3 results for Ziihera in gastric cancer
-
-
-
-
-
-
-
FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
-
-
-
-
-
-
-
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
-
331,995 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

